Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director, BC-Centre for Excellence in HIV/AIDS at Providence.

Slides:

Advertisements

Similar presentations

"Eliminating HIV Mother to Baby Transmission: A Status Report on Perinatal HIV in Florida " Ana M. Puga, MD- Medical Director Comprehensive Family AIDS.

Advertisements

Modelling the impact of male circumcision on HIV/AIDS in sub-Saharan Africa Brian Williams, SACEMA 14 November 2007.

Getting to Zero UNAIDS STRATEGY Ø Zero new HIV infections Ø Zero AIDS-related deaths Ø Zero discrimination CAJP-OAS/ Washington, April 2011.

9th Advanced HIV Course Aix-en-Provence 2011 Role of ARV as Prevention Martin Fisher Brighton and Sussex University Hospitals, UK.

1 TREATMENT AND PREVENTION SCALE-UP: THE SOUTH AFRICAN EXPERIENCE By Dr Moolman Team South Africa.

HIV-infection in Russia Alexander Panteleev Head of the HIV/TB department City TB Hospital # 2, St-Petersburg, Russia.

HIV/AIDS Results Monitoring and Evaluation Systems Measuring the Multi-Sector Response.

How Universal will Universal Access be in Europe by 2010? Eddy Beck Evaluation Department UNAIDS, Geneva

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the UK – 30 years on… Since 1981: 122,000 HIV diagnoses.

Monitoring the impact of vaccination on rubella and CRS Susan E. Reef, MD 11 th Annual Meeting The Measles and Rubella Initiative Sept. 19, 2012.

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.

The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.

South African National HIV Prevalence, Incidence and Behaviour Survey, 2012 Presenter: Prof LC Simbayi Executive Director, HAST Programme, Human Sciences.

Evidence based use of Stats SA data for implementation of HIV&AIDS Program Ms Y.Tsibolane FS DoH, HIV and AIDS Program Date: October 2013.

Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention.

HIV Surveillance Report, 2009 Minnesota Department of Health HIV/AIDS Surveillance System Minnesota Department of Health HIV/AIDS Surveillance System.

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,

Salim S Abdool Karim Pro Vice-Chancellor (Research), University of KwaZulu-Natal Director: CAPRISA - Centre for the AIDS Programme of Research in South.

Treatment as Prevention (TasP)

Stigma Research and Prevention Taweesap Siraprapasiri, MD National AIDS Management Center Disease Control Department Ministry of Public Health Evidence.

HIV/AIDS and Women: An Overview Global HIV/AIDS and Women: Current Challenges and Opportunities Briefing, Rayburn House Office Building Jen Kates, PhD.

Unprevented and prevented HIV cases in Europe and Central Asia Unprevented and prevented HIV cases in Europe and Central Asia Ani SHAKARISHVILI, MD UNAIDS.

HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.

Page 1 Peer-delivered HIV testing and counseling among people who inject drugs in Bangkok, Thailand Lianping Ti 1 Kanna Hayashi 1,2 Karyn Kaplan 3 Paisan.

Feasibility and acceptability of an antiretroviral treatment as prevention (TasP) intervention in rural South Africa Results from the ANRS TasP cluster-randomised.

Slide 1 of 42 IAS–USA Treatment as Prevention: Evaluating the Impact of HAART Expansion The British Columbia (BC) Experience AU EDITED FINAL:

Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.

Cristin Muecke, RMOH Nick Scott, ED AIDS NB.  Why HIV testing remains important  Treatment as prevention  Discuss advantages/disadvantages of various.

Treatment as prevention (TASP) for HIV and HCV: The evidence and modelling Peter Vickerman.

Accelerating Anti-Retroviral Treatment as a catalytic action for Ending AIDS Pride Chigwedere, MD, PhD Senior Advisor to the African Union AWA CONSULTATIVE.

Higher antiretroviral treatment coverage is associated with lower HIV infection rates: analysis of 51 low and middle-income countries Andrew Hill, Liverpool.

Melbourne, 23 July IAS 2014 Fatiha Terki, WFP Critical enablers and synergies including nutrition.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

AIDS 2014 – Ending the adolescent AIDS epidemic Ungdom og hiv Anne May Andersen, Norad.

The potential and challenges of ARV-based HIV prevention: An overview

HIV/AIDS: A Global and Regional Perspective AIDS in Post 2015 Development Agenda.

What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.

COUNTRY PRESENTATION (DRUGS AND HIV/AIDS)– Nepal Dr. Krishna Kumar Rai, Director National Centre for AIDS and STD Control, Ministry of Health and Population.

Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.

Slide 1 of 42 IAS–USA AU EDITED FINAL: Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director,

Epidemiologic overview of HIV/AIDS in Ontario and Toronto: 2004 update Robert S. Remis MD, MPH, FRCPC, Maraki Fikre Merid BSc Ontario HIV Epidemiologic.

Kevin Fenton, MD, PhD National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention August 5, 2008 Update on the US HIV/AIDS Crisis: Current Trends,

1 st International Treatment as Prevention (TasP) Workshop Overview British Columbia Centre for Excellence in HIV/AIDS Julio Montaner MD, DSc(hon), FRCPC,

British Columbia Centre for Excellence in HIV/AIDS Julio Montaner MD, FRCPC, FCCP, FRSC Director, BC-Centre for Excellence on HIV/AIDS, Providence Health.

Return on investment: How do whole societies benefit from improved services and coverage for key populations? Bradley Mathers Kirby Institute UNSW Australia.

Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

The HIV epidemic in Ontario: 2004 update Robert S. Remis, MD, MPH, FRCPC Ontario HIV Epidemiologic Monitoring Unit Department of Public Health Sciences,

Grinsztejn B, et al, Lancet Infect Dis, March 4 th 2014 PRIMARY COMBINED M&M OUTCOME FIRST AIDS DEFINING EVENT FIRST TB EVENT DEATH.

HIV and AIDS Data Hub for Asia-Pacific Review in slides Mongolia Last updated: December 2014.

Towards an improved investment approach for an effective response to HIV Dr Bernhard Schwartländer UNAIDS.

Global HIV Epidemiology Carey Farquhar, MD, MPH Grace John-Stewart MD, PhD Departments of Medicine, Epidemiology and Global Health.

Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,

Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.

Expanded PrEP implementation across Australia Expanded implementation of PrEP across Australia 1.

The HIV epidemic in Ontario: An epidemiologic update Robert S. Remis, MD, MPH, FRCPC, Department of Public Health Sciences, University of Toronto Presentation.

Contents - HIV global slides

Contribution of ALPHA results to global estimates and policy

“Its Different Now”: The Changing Landscape of HIV testing

Overview of Global HIV Epidemic

27 years of responding to AIDS

27 years of responding to AIDS

Global epidemiology of injecting drug use

WHO HIV update July 2018 Global epidemic Global progress and cascade

Stopping the Epidemic HIV Prevention Today

The HIV Epidemic among People who Inject Drugs

Correlates of Opioid and Benzodiazepine Co-Prescription Among People Living with HIV in British Columbia, Canada Stephanie Parent1, Seonaid Nolan2,3, Nadia.

Epidemiologic Update on the HIV Epidemic in Ontario

Presentation transcript:

Julio Montaner, MD Professor of Medicine, and Head, Div. of AIDS, University of British Columbia Director, BC-Centre for Excellence in HIV/AIDS at Providence Health Care UNAIDS Special Advisor on HIV Therapeutics Treatment as Prevention The Key to Eliminate AIDS & HIV AU EDITED FINAL: Special Technical Satellite, Melbourne 2014

The promise of HIV treatment: 1.Prevent HIV-related illness and disability 2.Avert AIDS-related deaths 3.Prevent new HIV infections

Increasing HAART Coverage within Evolving Guidelines in BC Source: Montaner et al, Lancet, 2010 January 2004 Summer of 1996 Summer of 2000 Phase I Phase II Phase III # of active participants on HAART in the HIV treatment programme

Source: Montaner et al, 2014 New AIDS Cases Diagnosed by Year British Columbia to 2013

> 90% Decrease in All Cause Mortality among HIV+ Individuals in BC, Canada since Years Frequency Source: Montaner et al, PLOS One, 12 Feb 2014

Source: Montaner et al, International AIDS Conference, 2014, Poster # TUPE203 New HIV Cases Diagnosed, Estimated HIV Incidence, & HAART Use by Year in BC

A clear correlation exists between HIV treatment and incidence Source: Tanser et al. Science 2013;339: % (0.8%-1.4%) reduction in HIV incidence, for each 1.0% increase in treatment coverage. ART & HIV incidence: Hlabisa, South Africa p=0.325 p=0.003 p=0.013 p= Incidence rate ratio ART coverage 0%30%60%

HIV incidence vs. ART coverage in 51 countries, weighted by epidemic size (2012 data) AIDS-related death rates vs. ART coverage in 51 countries, weighted by epidemic size (2012 data) Source: Hill, Pozniak, Raymond, Heath and Ford, AIDS 2014, 2014.

HIV Transmission According to Sexual Behavior Reported by HIV-Negative Partner Rate of Couple Transmission (per 100 Couple-Years Follow-Up) Heterosexual (Male) Vaginal sex with ejaculation (192 CYFU) Heterosexual (Female) Vaginal sex (272 CYFU) MSM Receptive anal sex: With ejaculation (93 CYFU) Without ejaculation (157 CYFU) Insertive anal sex (262 CYFU) Rate (95% CI) Overall risk = Zero through condomless sex with a partner on ART (HIV RNA <200 copies/mL Source: Rodger A, et al. 21 st CROI. Boston, Abstract 153LB

HIV treatment: The most effective biomedical intervention for the prevention of HIV transmission

Expanding ART for treatment and prevention of HIV in South Africa: Cost-effectiveness Lives Saved (x 1,000)U$A Billions Source: Granich et al, PLoS ONE 7(2):e30212, February 2013

By 2020… 90% of all people living with HIV will know their HIV status 90% of all people diagnosed with HIV will receive sustained antiretroviral therapy. 90% of all people receiving antiretroviral therapy will have durable suppression.

The result = a three-fold increase over current 2014 estimates 72 % of all people living with HIV will be virally suppressed 3

The new treatment paradigm Single target → Cascade target Death → Death and transmission Number → Equity Incremental funding→ Frontload Investments

The objective “Maximize the effectiveness of existing tools to virtually eliminate progression to AIDS, premature death and HIV transmission, and thereby transform the HIV/AIDS pandemic into a low level sporadic endemic.”

THE FINAL CHAPTER OF THE AIDS EPIDEMIC